Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
Development of a prime-boost anti-cancer vaccine. New vaccination strategies are urgently needed for a variety of diseases, including cancer. The problem with cancer vaccines is that it is difficult to trigger a response to a self protein. We propose that a prime-boost vaccination, using yellow fever virus and modified vaccinia virus ankara, could create very strong responses against tumor antigens. This approach can be patented and can revive that field of tumor vaccination, which is currently ....Development of a prime-boost anti-cancer vaccine. New vaccination strategies are urgently needed for a variety of diseases, including cancer. The problem with cancer vaccines is that it is difficult to trigger a response to a self protein. We propose that a prime-boost vaccination, using yellow fever virus and modified vaccinia virus ankara, could create very strong responses against tumor antigens. This approach can be patented and can revive that field of tumor vaccination, which is currently restrained by the difficulty of breaking immunological tolerance. We envisage the construction of a anti-cancer vaccine vector with obvious market potential. An exciting prospect is that this approach could be used as a prophylactic vaccine and possibly also as a therapeutic vaccine.Read moreRead less